Processa Pharmaceuticals, Inc.: 10-Q filed 2017-10-04

Name: Processa Pharmaceuticals, Inc.: 10-Q filed 2017-10-04
Creator: Processa Pharmaceuticals, Inc.

What Processa Pharmaceuticals, Inc. reported in its quarterly report filed 2017-10-04 (fiscal Q2 2017): 26 published measures, 61 facts as tagged in accession 0001393905-17-000302.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-10-04
Fiscal period: fiscal Q2 2017
Accession: 0001393905-17-000302 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Processa Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-06-30	1,949	USD
At 2016-12-31	3,237	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-06-30	2,492,877	USD
At 2016-12-31	2,354,393	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-06-30	-2,490,928	USD
At 2016-12-31	-2,351,156	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2017-06-30	1,949	USD
At 2016-12-31	3,237	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-04-01 to 2017-06-30	-42,851	USD	91
2017-01-01 to 2017-06-30	-118,478	USD	181
2016-04-01 to 2016-06-30	-43,200	USD	91
2016-01-01 to 2016-06-30	-176,825	USD	182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-01-01 to 2017-06-30	-76,288	USD	181
2016-01-01 to 2016-06-30	-52,942	USD	182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2016-01-01 to 2016-06-30	5,000	USD	182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-01-01 to 2017-06-30	75,000	USD	181
2016-01-01 to 2016-06-30	15,000	USD	182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2016-01-01 to 2016-06-30	42,000	USD	182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-06-30	-15,394,689	USD
At 2016-12-31	-15,254,917	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2016-01-01 to 2016-06-30	6,691	USD	182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-06-30	1,949	USD
At 2016-12-31	3,237	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2017-04-01 to 2017-06-30	63,410	USD	91
2017-01-01 to 2017-06-30	125,355	USD	181
2016-04-01 to 2016-06-30	62,634	USD	91
2016-01-01 to 2016-06-30	118,740	USD	182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-06-30	2,492,877	USD
At 2016-12-31	2,354,393	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-06-30	91,187	USD
At 2016-12-31	166,165	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2017-04-01 to 2017-06-30	10,353	USD	91
2017-01-01 to 2017-06-30	24,035	USD	181
2016-04-01 to 2016-06-30	8,981	USD	91
2016-01-01 to 2016-06-30	89,496	USD	182

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2016-01-01 to 2016-06-30	5,000	USD	182

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2017-04-01 to 2017-06-30	10,270	USD	91
2017-01-01 to 2017-06-30	23,869	USD	181
2016-04-01 to 2016-06-30	3,284	USD	91
2016-01-01 to 2016-06-30	83,799	USD	182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-04-01 to 2017-06-30	83	USD	91
2017-01-01 to 2017-06-30	166	USD	181
2016-04-01 to 2016-06-30	5,697	USD	91
2016-01-01 to 2016-06-30	5,697	USD	182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-06-30	11,017,388	shares
At 2016-12-31	11,017,388	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-06-30	14,329,057	USD
At 2016-12-31	14,329,057	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2017-06-30	147,619	USD
At 2016-12-31	134,513	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2017-04-01 to 2017-06-30	-42,851	USD	91
2017-01-01 to 2017-06-30	-118,478	USD	181
2016-04-01 to 2016-06-30	-46,460	USD	91
2016-01-01 to 2016-06-30	-178,081	USD	182

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2017-04-01 to 2017-06-30	-53,557	USD	91
2017-01-01 to 2017-06-30	-139,772	USD	181
2016-04-01 to 2016-06-30	-53,906	USD	91
2016-01-01 to 2016-06-30	-198,236	USD	182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2016-01-01 to 2016-06-30	159	USD	182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-06-30	-44,066	USD	181
2016-01-01 to 2016-06-30	17,829	USD	182

Inspect the source

Entity: Processa Pharmaceuticals, Inc. / CIK 0001533743
Captured: 2026-09-20T09:16:31.348Z
SEC response SHA-256: 5f3216d9024f2a7fc94b315f5bf243c7efb048273a6be394a2f74186d7af2a31

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001533743.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))